Walden Group Healthcare M&A Blog

  • Rapid Growth for Gene Therapy

    Large pharmaceutical and diagnostic players companies have been acquiring emerging gene and cell therapy companies with promising drug pipelines or drug approvals, some with limited revenue. In March 2019, Thermo Fisher Scientific agreed to pay $1.7b to acquire Brammer Bio, which offers pre-clinical and analytical development, process...
    Read More
  • Catalent to Acquire Paragon Bioservices for $1.2b

    Catalent, Inc., a $2.46b provider of delivery technologies for drugs, biologics, and consumer and animal health products, is buying Paragon Bioservices, Inc., a developer of viral vectors for gene therapies. The deal Complements Catalent's biologics business. Paragon engages in the production and purification of therapeutic proteins, monoclonal...
    Read More
  • Smith & Nephew to Buy Osiris Therapeutics

    Smith & Nephew plc (LSE:SN, NYSE:SNN), a $4.9b maker of orthopedic, wound management, sports medicine and trauma & extremities products, is acquiring Osiris Therapeutics, Inc., a provider of regenerative medicine products, including skin, bone graft and articular cartilage substitutes. The deal accelerates S&N's wound management...
    Read More
  • Medtronic to Acquire EPIX Therapeutics

    Medtronic plc (NYSE: MDT), a $29.95b manufacturer of cardio-vascular, orthopedic, spinal and other medical devices., is buying EPIX Therapeutics, Inc. (formerly Advanced Cardiac Therapeutics), a maker of a catheter-based, temperature-controlled cardiac ablation systems. The acquisition expands Medtronic's cardiac ablation portfolio. EPIX...
    Read More
  • Abbott Laboratories to Acquire Cephea Valve Technologies

    Abbott Laboratories, a $20.4b global developer of diagnostics, medical devices, nutritionals and branded generic pharmaceuticals is buying Cephea Valve Technologies, Inc, a developer of a less-invasive heart valve replacement technology for mitral valve disease. The deal Strengthens Abbott's in structural heart therapies. Cephea's artificial...
    Read More